Conferences - Results from #9660

ASCO 2017: Updated efficacy and safety of avelumab in metastatic urothelial carcinoma (mUC): Pooled analysis from 2 cohorts of the phase 1b Javelin solid tumor study June 5, 2017

ASCO 2017: Challenges in Translating Molecular Results Into Meaningful Clinical Use June 5, 2017

ASCO 2017: Health-related quality of life as a marker of treatment benefit with nivolumab in platinum-refractory patients with metastatic or unresectable urothelial carcinoma from CheckMate 275 June 5, 2017

ASCO 2017: Inter and intra-tumor heterogeneity of PD-L1 and MET expression in metastatic renal cell carcinoma June 5, 2017

ASCO 2017: The Dynamic Landscape of Renal Cell Carcinoma Biomarkers: Can We Predict Prognosis, Treatment Response, and Outcome? June 5, 2017

ASCO 2017: Phase 3 KEYNOTE-361 trial: Pembrolizumab with or without chemotherapy versus chemotherapy alone in advanced urothelial cancer June 5, 2017

ASCO 2017: Prognostic role of circulating tumor cells in metastatic renal cell carcinoma June 5, 2017

ASCO 2017: Results of LATITUDE: ADT with Abiraterone Acetate Plus Prednisone in High-Risk Metastatic Hormone-Naive Prostate Cancer June 5, 2017

ASCO 2017: Microvessel density as a prognostic marker in high-risk renal cell carcinoma June 5, 2017

ASCO 2017: Efficacy and safety of nivolumab in patients with metastatic renal cell carcinoma and brain metastases: Preliminary results from the GETUG-AFU 26 (Nivoren) study June 5, 2017

ASCO 2017: Intermediate prognosis in metastatic germ cell tumors: Outcome and prognostic factors June 5, 2017

ASCO 2017: Applying radiomics to predict pathology of post chemotherapy retroperitoneal nodal masses in germ cell tumors June 5, 2017

ASCO 2017: High-dose chemotherapy plus peripheral-blood stem-cell transplant for patients with relapsed germ-cell tumors and active brain metastases June 5, 2017

ASCO 2017: Histologic determinants of long-term overall survival in patients with germ cell tumors June 5, 2017

ASCO 2017: Predictors of urinary diversion choice in patients with bladder cancer in integrated care settings June 4, 2017

ASCO 2017: Safety and efficacy of docetaxel + b-701, a selective inhibitor of FGFR3, in subjects with advanced or metastatic urothelial carcinoma June 4, 2017

ASCO 2017: Spectrum of tumor mutational load in genitourinary cancers June 4, 2017

ASCO 2017: Phase I/II trial of cetuximab with 5-fluorouracil and mitomycin C concurrent with radiotherapy in patients with muscle invasive bladder cancer June 4, 2017

ASCO 2017: Updated efficacy and tolerability of durvalumab in locally advanced or metastatic urothelial carcinoma (UC) June 4, 2017

ASCO 2017: Exploring Novel Dosing and Combination Strategies in Metastatic Renal Cell Carcinoma June 4, 2017

Page 484 of 616